Tenax Therapeutics
TENX | NASDAQ
$1.48
-$0.14 (-8.64%)
At close: Nov 16, 2026, 4:00 PM ET
$1.48
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Tenax Therapeutics Company Profile
Company profile explainedCompany Profile
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Key Executives
| Name | Position |
|---|---|
| Christopher T. Giordano | Chief Executive Officer, President & Director |
| Thomas R. Staab | Chief Financial Officer |
| Doug Randall | Chief Business Officer |
| Douglas Hay | Executive Vice President of Regulatory Affairs |
| So-Young Kim | Executive Vice President of Clinical Development & Strategy |
| Stuart Rich | Chief Medical Officer & Director |
| Thomas A. McGauley | Principal Financial Officer & Principal Accounting Officer |
| Timothy G. Healey | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 21, 2026 | 4 | Filing |
| Oct 15, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 09, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 08, 2026 | 8-K | Current Report |
| Sep 17, 2026 | 4 | Filing |
| Sep 15, 2026 | 4 | Filing |
| Sep 15, 2026 | 4 | Filing |
| Sep 11, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Tenax Therapeutics
| Country | United States |
| IPO Date | Apr 4, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Christopher T. Giordano |
Contact Details
101 Glen Lennox Drive Chapel Hill,
North Carolina 27517 United States
Stock Details
| Ticker Symbol | TENX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000034956 |
| CUSIP Number | 88032L605 |
| ISIN Number | US88032L6056 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove TENX